| Attributes | Values |
|---|
| rdf:type
| |
| description
| - wetenschappelijk artikel (nl)
- наукова стаття, опублікована в березні 2002 (uk)
- im März 2002 veröffentlichter wissenschaftlicher Artikel (de)
- artículu científicu espublizáu en marzu de 2002 (ast)
- scientific article published on 01 March 2002 (en)
|
| publication date
| |
| publication date
| |
| author name string
| |
| author name string
| - Larry W Moreland
- Michael E Weinblatt
- Michael Schiff
- Joel Kremer
- Eric Hurd
- Dorothy McCabe
- John Cush
- William J Rich
- Moraye B Bear
|
| rdfs:label
| - Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial (en)
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial (nl)
|
| skos:prefLabel
| - Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial (en)
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial (nl)
|
| name
| - Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial (en)
- Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial (nl)
|
| author
| |
| author
| |
| title
| |
| title
| - Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| |
| is about
of | |
| is cites work
of | - De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases
- Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis
- Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
- Gene polymorphisms and pharmacogenetics in rheumatoid arthritis
- Infection complications associated with the use of biologic agents
- Pathogenic roles of B cells in human autoimmunity; insights from the clinic
- The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders
- Anakinra for rheumatoid arthritis
- Caspase functions in cell death and disease
- Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis.
- Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy
- Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
- Use of biologics in rheumatoid arthritis: current and emerging paradigms of care
- IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders
- Interleukin-1 receptor blockade in perinatal brain injury
- Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis
- A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
- Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability
- Targeting interleukin-1 in the treatment of rheumatoid arthritis
- IL-1 pathways in inflammation and human diseases
- Adverse effects of biologics: a network meta-analysis and Cochrane overview
- The balance between IL-1 and IL-1Ra in disease
- Pharmacotherapy options in rheumatoid arthritis
- Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities
- Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation
- Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects
- Therapy Insight: fibromyalgia--a different type of pain needing a different type of treatment
- Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling
- Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice
- Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules
- The treatment of rheumatoid arthritis
- A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate
- Safety of extended treatment with anakinra in patients with rheumatoid arthritis
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)